The Association of the British Pharmaceutical Industry (ABPI) Code of Practice is currently in a review and update process, intended to produce a revised version of the Code which will have effect from 1 July 2021.
The ABPI has stated that following market research last year, they are looking to improve accessibility and future-proof the Code. Certain other amendments are required to ensure consistency with the recent consolidation of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code, which the ABPI (as an EFPIA member) must comply with.
Of particular note among the changes is the introduction of the concept of 'collaborative working'. This expands the existing permission for 'joint working' with the NHS by allowing projects which may benefit the NHS without the current need to show direct benefit to patients too (although, as you would expect, levels of patient care must at least be maintained by the collaboration).
Should you wish to participate in the consultation, the proposed 2021 ABPI Code can be found here.
PMCPA guidance to the 2021 Code has also been published here.
The consultation is public and open to all, with a closing date of 8 September 2020. Submissions are welcomed from across the industry.
We would also welcome hearing your thoughts on the new ABPI Code of Practice.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
